Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GH
HOLDGuardant Health, Inc. · Healthcare · United States · $19.5B · Avg Vol: $438M/d
COMPANY DESCRIPTION
Guardant Health, Inc. is a leading precision oncology company specializing in advanced liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection. Its competitive advantage stems from proprietary genomic profiling technology, extensive clinical validation, and a strong market position as a pioneer in non-invasive cancer diagnostics. The company collaborates with pharmaceutical partners to accelerate precision medicine in oncology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 449.5M | 563.9M | 739.0M | 982.0M | 29.8% | 1.1B | 1.3B | 1.7B | 32.2% |
| EPS | -6.41 | -4.28 | -3.56 | -3.32 | — | -3.23 | — | — | — |
| Shares | 102.6M | 121.6M | 124.0M | 130.6M | +27.3% | 132.6M | — | — | — |
| Debt | 1.4B | 1.4B | 1.3B | 1.7B | 7.7% | 1.7B | — | — | — |
| Equity | 60.2M | 158.7M | -139.6M | -99.3M | 163.7% | — | — | — | — |
| Op CF | -309.5M | -325.0M | -239.9M | -184.8M | — | -187.7M | — | — | — |
| Inv CF | 149.8M | 840.3M | -261.3M | -627.2M | — | — | — | — | — |
| Fin CF | -189.1M | 477.4M | -1.0M | 671.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GH | Guardant Health, Inc.(you) | $19.5B | 47 | HOLD |
| NTRA | Natera, Inc. | $37.5B | 52 | HOLD |
| TWST | Twist Bioscience Corporation | $5.6B | 45 | HOLD |
| RVTY | Revvity, Inc. | $12.3B | 65 | BUY |
| IDXX | IDEXX Laboratories, Inc. | $42.9B | 59 | HOLD |
| BLLN | BillionToOne, Inc. | $5.8B | 41 | HOLD |
| WAT | Waters Corporation | $36.8B | 65 | BUY |
| IQV | IQVIA Holdings Inc. | $34.7B | 67 | BUY |
| CRL | Charles River Laboratories International, Inc. | $10.9B | 69 | BUY |
| MEDP | Medpace Holdings, Inc. | $16.8B | 78 | BUY |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%